The Scalp That Cannot Grow It Back

Why CCCA and frontal fibrosing alopecia require a different foundation, a different attachment, and a different plan

A woman sits in the chair and tells you her crown has been thinning for six years. She has been told it is breakage. She has been told it is stress. She has been told to stop wearing her hair up. Somewhere in there, someone sold her a topper with pressure-sensitive clips and told her to wear it every day.

Look closely at the vertex. The skin is smooth and slightly shiny. The follicular openings are gone. Not sparse. Gone.

Those findings are not typical thinning. They raise concern for a scarring alopecia and warrant dermatologic evaluation. If follicles have been replaced by fibrosis, that loss is permanent, and the fitting you were about to do could add mechanical stress to tissue that has none to spare.

Scarring alopecia is the category our profession is least prepared for, and it walks through the door more often than most practitioners realize. It deserves a foundation strategy of its own.

What makes cicatricial alopecia different

In non-scarring hair loss, the follicle is still there. It may be miniaturized, dormant, or shedding early, but the machinery survives. Growth remains possible.

In cicatricial alopecia, inflammation destroys the follicular stem cell reservoir and replaces the follicle with fibrous tissue. Once a follicle has been fully replaced by scar, it does not regenerate. Treatment aims to halt progression and protect what survives. Regenerative therapies are being studied and we address them below, though none of them rebuild a follicle that is already gone.

This changes the entire premise of a fitting. We are not covering a temporary condition while we wait for regrowth. We are protecting a limited, non-renewable population of surviving follicles at the border of an active disease.

Two presentations are especially important in cranial prosthesis practice.

Central centrifugal cicatricial alopecia (CCCA) begins at the vertex and expands outward in a symmetric, centrifugal pattern. It is the most common primary scarring alopecia in women of African descent, with reported prevalence between 2.7 and 5.7 percent. Genetic susceptibility is well documented, including loss-of-function variants in PADI3, a gene involved in hair shaft formation, identified in roughly a third of a small discovery cohort of 16 affected women. High-tension styling, chemical relaxers, and heat are discussed in the literature as aggravating factors rather than sole causes.

CCCA is also diagnosed late. A 2025 review found that patients with CCCA waited significantly longer for diagnosis than patients with other scarring alopecias. By the time she reaches your chair, years of follicular loss may already be permanent.

Frontal fibrosing alopecia (FFA) takes the opposite territory. It produces a receding band across the frontal and temporal hairline, often with pale, shiny, atrophied skin and isolated surviving hairs stranded ahead of the new margin. Between 50 and 83 percent of patients also lose eyebrows, and sideburn involvement is common. It occurs most often in postmenopausal women, and its incidence has climbed worldwide over the past two decades. Case-control studies have examined associations with facial skincare products, sunscreens, hormonal exposures, thyroid disease, and formalin-based straightening, though causation remains unsettled.

The distinction matters at the fitting table. CCCA expands from the center. FFA retreats from the front. One takes the crown you would build a topper over. The other takes the hairline you would attach to.

The part almost nobody in this industry is taught

Physical trauma has been reported to precipitate new lesions or disease activity in susceptible patients with some forms of scarring alopecia, particularly lichen planopilaris and its frontal fibrosing variant. This is the Koebner phenomenon.

The literature on this is not theoretical. Lichen planopilaris has been reported after hair transplantation in multiple case series, including one report of 17 patients. It has been reported after face-lift surgery. It has been reported in firefighters whose helmets applied sustained pressure and friction to the scalp.

And it has been reported from wig wear.

There is a published case of a woman with lichen planopilaris who developed new plaques of scarring alopecia attributed to the pressure of her wig fasteners and the traction of removing adhesive tape. A separate report describes lichen planopilaris arising from wig attachment in a patient with frontal fibrosing alopecia.

Read that again, because it reframes the job entirely. In this population, the attachment method is not a comfort decision. It is a disease variable.

Clips create focal, repeated tension at fixed anchor points. Adhesive removal creates traction and epidermal stripping at the frontal margin. In FFA, that margin is the disease. We are being asked to secure a prosthesis to the exact tissue we most need to leave alone.

What about PRP and PRF

Clients ask this, and they should. There are published reports of hair density improving in scarring alopecia after platelet-rich plasma injections, including in CCCA, and the question deserves an accurate answer rather than a dismissal.

Case reports have documented improved follicular density in patients with stabilized disease after three consecutive monthly sessions. A 2023 JAAD abstract evaluating PRP in cicatricial alopecia reported decreased clinical signs or symptoms and/or increased hair density and thickness in 15 of 19 patients with reported post-treatment outcomes. A randomized blinded trial in lichen planopilaris was published in 2024. These are encouraging signals from a small retrospective evidence base, not established practice.

What improves most consistently, though, is disease activity rather than follicular regeneration. A 2025 systematic review of procedural treatments found that platelet products most reliably reduced activity scores and improved symptoms, with some reports also showing gains in terminal hair counts or shaft diameter. Quieting inflammation in a disease that destroys follicles through inflammation is a meaningful outcome. It is a different claim from regrowing scar.

Three qualifiers belong in any honest conversation with a client. Benefit has been reported in stabilized disease, and at least one CCCA report describes the growth as transitory, with density declining again roughly six months later and maintenance sessions required to hold it. Many of these patients carry concurrent androgenetic alopecia, so part of what responds may be the non-scarred component. And results are inconsistent: one FFA patient treated every four weeks for sixteen weeks showed no significant change in follicular units or density. A randomized placebo-controlled trial of PRP in CCCA is registered on ClinicalTrials.gov, but the current registry record lists the study as not yet recruiting, which is another indication that this question remains unresolved.

Two points for practitioners. First, this is a physician-administered medical treatment, and recommending it is outside our scope. Our role is to know it exists, understand what it can and cannot do, and support the client’s dermatologic plan rather than compete with it. Second, PRP does not remove the need for sound foundation design. A client stabilizing on injections is still wearing a prosthesis for many hours a day, and the mechanical load we place on her scalp continues either way.

Worth noting for balance: a 2020 case series specifically examined whether PRP injections would trigger new disease in lichen planopilaris and its variants and reported tolerability without koebnerization. That is a controlled clinical procedure performed by a physician, which is not comparable to sustained daily clip tension or repeated adhesive removal at an inflamed margin. The distinction is between a single controlled event and continuous mechanical stress, and it is worth stating plainly rather than blurring.

Foundation design in active or recent disease

The following are the design principles we apply to scarring alopecia cases. They are clinical positions, not preferences.

Distribute the hold. Never anchor it.

Full-cap construction with a well-engineered adjustable perimeter distributes weight across the whole head. Clip-based toppers concentrate force into a handful of points, and those points are usually in surviving hair at the border of the lesion, which is precisely the tissue with the most to lose. When a topper is genuinely the right answer for coverage, the retention has to come from base design and fit accuracy, not from grip strength.

Keep adhesives off the disease margin.

In FFA, that means keeping bonding agents and tapes away from the frontal and temporal hairline. Removal traction and solvent exposure at an actively inflamed margin is a poor trade for a cleaner front. Where a client needs an undetectable front, we would rather solve it with foundation engineering and hair direction than with chemistry applied to fragile tissue.

Reduce weight before you reduce anything else.

Where the scalp is atrophic, inflamed, tender, or structurally compromised, unnecessary mechanical load should be minimized. We reduce density and reconsider excessive length when either would increase sustained load on vulnerable tissue. Length is a load decision and deserves an honest conversation rather than a silent build.

Build for a moving perimeter.

CCCA expands. FFA recedes. A foundation cut to today’s margin may be sitting on newly involved tissue in eight months. We plan measurement intervals into the case from the start and design bases that tolerate adjustment rather than requiring replacement.

Preserve access to the scalp.

Many of these clients are on prescribed topicals, intralesional injections, or oral therapy. The foundation cannot obstruct the treatment plan. Bases should permit direct application and thorough cleansing, and clients should be counseled on wear intervals that allow the scalp to be treated on schedule. Occlusion also alters the local environment for any product applied beneath it, which is worth raising with the prescribing dermatologist rather than deciding alone.

Choose materials for a compromised barrier, not for a catalog.

Choose smooth, low-friction contact surfaces and foundation structures that minimize unnecessary occlusion and permit effective cleansing and drying. No coarse netting against fragile skin, no unnecessary polyurethane or silicone perimeter sitting on inflamed tissue, and no interior seam the client can feel. Every material decision should be defensible in terms of contact, friction, occlusion, and hygiene rather than in terms of what the supplier calls it.

What to look for and what to say

Practitioners do not diagnose. We observe, document, and refer.

Signs worth noting in the chair include loss of visible follicular openings, shiny or waxy skin, perifollicular redness or scale, tenderness, burning, persistent itching, tufting of multiple hairs from one opening, a hairline that has moved back with pale skin behind it, sideburn thinning, and eyebrow loss. 

When these appear, the professional response is a referral for dermatologic evaluation, ideally to a dermatologist experienced in hair and scalp disorders, who can determine whether trichoscopy, biopsy, or other evaluation is appropriate. Reviews describe scalp biopsy as the standard for definitive diagnosis, while clinical and trichoscopic findings can strongly suggest it.

What we can say to the client is plain and useful. Something on her scalp is worth having examined by a physician. In the meantime, we will build in a way that does not add mechanical stress to it.

What we should not do is fit aggressively, promise regrowth, or sell a maintenance regimen that substitutes for medical care. The most valuable thing a practitioner can do for a woman in the early stage of CCCA is get her diagnosed while she still has follicles left to protect.

The eyebrow conversation

For FFA clients, eyebrow loss is often the harder emotional loss. It is visible in every conversation, in every photograph, and in the mirror at close range. Prosthetic hair planning should include a discussion of eyebrow options and of where dermatologic treatment may be attempting stabilization or regrowth. This is one more reason to coordinate rather than work in isolation.

Why this belongs in professional training

The industry standard response to a scarred scalp is to cover it and sell the unit. The clinical standard is to treat the fitting as an intervention with the capacity to help or to harm.

Scarring alopecia sits at the intersection of dermatology and prosthetic design. It requires an understanding of tissue behavior, load distribution, material contact, disease progression, and referral pathways. That is not a product problem. It is a training problem, and it is the reason our certification curriculum begins with the scalp instead of with the hair.

The follicles already lost to fibrosis are not coming back, and the ones still standing are the whole inventory. Everything we build should be designed around that fact.

References

1. Dlova NC, Salkey KS, Callender VD, McMichael AJ. Central Centrifugal Cicatricial Alopecia: New Insights and a Call for Action. Journal of Investigative Dermatology Symposium Proceedings. 2017;18(2):S54-S56. https://pubmed.ncbi.nlm.nih.gov/28941495/

2. Wang KL, Pincelli TP, Wentworth AB, et al. Central centrifugal cicatricial alopecia: retrospective case-control study of 54 patients from a tertiary care center. International Journal of Women’s Dermatology. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12047870/

3. Balazic E, Chen A, Konisky H, et al. A retrospective chart review of central centrifugal cicatricial alopecia patients at a single urban institution. JAAD International. 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10494455/

4. Issa T, Klomhaus AM, Kasakevich C, Pickford J, Goh C. Central centrifugal cicatricial alopecia is associated with longer time to diagnosis among scarring alopecias. JAAD International. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12814682/

5. Frontal Fibrosing Alopecia: A Comprehensive Review with Recent Updates. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11952711/

6. Miao YJ, Jing J, Du XF, et al. Frontal fibrosing alopecia: A review of disease pathogenesis. Frontiers in Medicine. 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357920/

7. Eyebrow hair loss as a prognostic factor for frontal fibrosing alopecia. JAAD International. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9460816/

8. Ramos PM, Anzai A, Duque-Estrada B, et al. Risk factors for frontal fibrosing alopecia: A case-control study in a multiracial population. Journal of the American Academy of Dermatology. 2021. https://www.sciencedirect.com/science/article/abs/pii/S0190962220324725

9. Moreno-Arrones OM, Saceda-Corralo D, Rodrigues-Barata AR, et al. Risk factors associated with frontal fibrosing alopecia: a multicentre case-control study. Clinical and Experimental Dermatology. 2019. https://pubmed.ncbi.nlm.nih.gov/30259544/

10. Follicular Lichen Planus Caused by Wig Use: An Unusual Case of Koebner Phenomenon. Actas Dermo-Sifiliográficas. 2016. https://www.actasdermo.org/en-follicular-lichen-planus-caused-by-articulo-S1578219016300324

11. Taguti P, Dutra H, Trüeb RM. Lichen Planopilaris Caused by Wig Attachment: A Case of Koebner Phenomenon in Frontal Fibrosing Alopecia. International Journal of Trichology. 2018;10(4):172-174. doi:10.4103/ijt.ijt_48_18. PMID:30386077. https://pubmed.ncbi.nlm.nih.gov/30386077/

12. Scalp trauma in lichen planopilaris: Case reports of disease progression from fire fighter helmet use. JAAD Case Reports. 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11111581/

13. Donovan J. Lichen planopilaris after hair transplantation: report of 17 cases. Dermatologic Surgery. 2012. https://pubmed.ncbi.nlm.nih.gov/23205573/

14. Chiang YZ, Tosti A, Chaudhry IH, et al. Lichen planopilaris following hair transplantation and face-lift surgery. British Journal of Dermatology. 2012. https://pubmed.ncbi.nlm.nih.gov/21985326/

15. Cleveland Clinic. Frontal Fibrosing Alopecia: Symptoms, Causes and Treatments. https://my.clevelandclinic.org/health/diseases/23316-frontal-fibrosing-alopecia

16. A systematic review of procedural modalities in the treatment of lichen planopilaris, frontal fibrosing alopecia, and discoid lupus erythematosus. 2025. https://pubmed.ncbi.nlm.nih.gov/41081974/

17. Svigos K, Yin L, Shaw K, et al. Use of platelet-rich plasma in lichen planopilaris and its variants: A retrospective case series demonstrating treatment tolerability without koebnerization. Journal of the American Academy of Dermatology. 2020. https://www.jaad.org/article/S0190-9622(20)31087-2/abstract

18. Behrangi E, et al. Platelet-rich plasma as a new and successful treatment for lichen planopilaris: A controlled blinded randomized clinical trial. Journal of Cosmetic Dermatology. 2024. https://onlinelibrary.wiley.com/doi/10.1111/jocd.16302

19. Park M, Suh S, Babadjoui A, Atanaskova N. Growing uses of PRP: an evaluation of hair growth in cicatricial alopecia. Journal of the American Academy of Dermatology. 2023;89(3 Suppl):AB171. doi:10.1016/j.jaad.2023.07.687. https://doi.org/10.1016/j.jaad.2023.07.687

20. Transitory hair growth using platelet-rich plasma therapy in stabilized central centrifugal cicatricial alopecia. 2022. https://pubmed.ncbi.nlm.nih.gov/36042537/

21. Platelet Rich Plasma in the Treatment of Frontal Fibrosing Alopecia. https://www.heraldopenaccess.us/openaccess/platelet-rich-plasma-in-the-treatment-of-frontal-fibrosing-alopecia

22. Effect of Platelet-Rich Plasma Versus Placebo in the Treatment of Central Centrifugal Cicatricial Alopecia. Baylor College of Medicine. ClinicalTrials.gov NCT06998433. https://clinicaltrials.gov/study/NCT06998433

© Hairline Illusions™ | HIASTI | Hair & Wig Science Series. All rights reserved. This article is for professional education and is not a substitute for individualized medical evaluation. No portion of this publication may be reproduced, distributed, transmitted, or excerpted in any form or by any means, including digital, print, or screenshot, without prior written permission from Hairline Illusions LLC.